ANRO
Alto Neuroscience Inc.

1,104
Mkt Cap
$472.83M
Volume
88,887.00
52W High
$20.91
52W Low
$1.60
PE Ratio
-6.61
ANRO Fundamentals
Price
$16.38
Prev Close
$15.22
Open
$15.20
50D MA
$16.15
Beta
1.67
Avg. Volume
186,376.25
EPS (Annual)
-$2.50
P/B
3.71
Rev/Employee
$0.00
$47.22
Loading...
Loading...
News
all
press releases
Alto Neuroscience, Inc. (NYSE:ANRO) Given Average Recommendation of "Moderate Buy" by Analysts
Alto Neuroscience, Inc. (NYSE:ANRO - Get Free Report) has received an average rating of "Moderate Buy" from the eight ratings firms that are currently covering the company, Marketbeat.com reports...
MarketBeat·8h ago
News Placeholder
More News
News Placeholder
Alto Neuroscience Highlights Invited Review in American Journal of Psychiatry Establishing Neuroplasticity as a Core Driver of Psychiatric Disease and Treatment
Alto Neuroscience, Inc. (Alto) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced the...
Business Wire·6d ago
News Placeholder
Short Interest in Alto Neuroscience, Inc. (NYSE:ANRO) Drops By 21.0%
Alto Neuroscience, Inc. (NYSE:ANRO - Get Free Report) was the target of a significant drop in short interest during the month of December. As of December 31st, there was short interest totaling...
MarketBeat·22d ago
News Placeholder
Alto Neuroscience, Inc. (NYSE:ANRO) Given Average Recommendation of "Moderate Buy" by Brokerages
Shares of Alto Neuroscience, Inc. (NYSE:ANRO - Get Free Report) have been assigned an average rating of "Moderate Buy" from the eight research firms that are currently covering the firm...
MarketBeat·25d ago
News Placeholder
Alto Neuroscience Presents New Data at the 64th Annual Meeting of the American College of Neuropsychopharmacology
Alto Neuroscience, Inc. (Alto) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced...
Business Wire·27d ago
News Placeholder
Alto Neuroscience (NYSE:ANRO) Stock Price Up 8.1% - What's Next?
Alto Neuroscience (NYSE:ANRO) Trading 8.1% Higher - What's Next...
MarketBeat·1mo ago
News Placeholder
Chardan Capital Raises Alto Neuroscience (NYSE:ANRO) Price Target to $30.00
Chardan Capital lifted their target price on shares of Alto Neuroscience from $15.00 to $30.00 and gave the stock a "buy" rating in a research note on Monday...
MarketBeat·1mo ago
News Placeholder
Alto Neuroscience (NYSE:ANRO) Shares Down 6% - What's Next?
Alto Neuroscience (NYSE:ANRO) Shares Down 6% - Here's What Happened...
MarketBeat·1mo ago
News Placeholder
Alto Neuroscience (NYSE:ANRO) Stock Price Down 5.6% - Here's Why
Alto Neuroscience (NYSE:ANRO) Stock Price Down 5.6% - Here's What Happened...
MarketBeat·1mo ago
News Placeholder
Alto Neuroscience, Inc. (NYSE:ANRO) Receives Consensus Rating of "Moderate Buy" from Analysts
Alto Neuroscience, Inc. (NYSE:ANRO - Get Free Report) has been assigned an average rating of "Moderate Buy" from the eight brokerages that are covering the stock, MarketBeat.com reports. One analyst...
MarketBeat·2mo ago
<
1
2
...
>

Latest ANRO News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.